Combining radium-223 with enzalutamide offered a survival benefit in metastatic castration-resistant prostate cancer, but experts questioned its relevance in a shifting treatment landscape.
Deborah Mukherji discussing two abstracts including “RAPSON: Open-label, multicenter randomized trial of Radium-223 -> docetaxel versus docetaxel -> Radium-223 sequence in mCRPC with prospective ...